Chemical Compound Review:
Cormelian 3-[4-[3-(3,4,5- trimethoxyphenyl)carbonylox...
Synonyms:
Dilazep, Dilazepam, Dilazepum, Labitan, Tocris-0481, ...
- A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin). Cass, C.E., King, K.M., Montaño, J.T., Janowska-Wieczorek, A. Cancer Res. (1992)
- Effect of dilazep dihydrochloride against ischemia and reperfusion-induced disruption of blood-brain barrier in rats: a quantitative study. Kawagoe, J., Abe, K., Ikuta, J., Igarashi, N., Shimizu, S., Yamauchi, Y., Kogure, K. Naunyn Schmiedebergs Arch. Pharmacol. (1992)
- Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells. Sonoki, K., Iwase, M., Iino, K., Ichikawa, K., Yoshinari, M., Ohdo, S., Higuchi, S., Iida, M. Eur. J. Pharmacol. (2003)
- Central nervous system effects and behavioral interactions with ethanol of centrally administered dilazep and its metabolites in mice. Dar, M.S. Eur. J. Pharmacol. (1989)
- Intravenous dilazep reduces blood pressure and peripheral vascular resistance in humans. Poggesi, L., Masotti, G., Serneri, G.G., Carnovali, M. Journal of clinical pharmacology. (1988)
- Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Zhou, H., Wolberg, A.S., Roubey, R.A. Blood (2004)
- Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Deguchi, H., Takeya, H., Wada, H., Gabazza, E.C., Hayashi, N., Urano, H., Suzuki, K. Blood (1997)
- Diameter change and pressure-red blood cell velocity relations in coronary microvessels during long diastoles in the canine left ventricle. Kanatsuka, H., Ashikawa, K., Komaru, T., Suzuki, T., Takishima, T. Circ. Res. (1990)
- Dipyridamole and dilazep suppress oxygen radicals in puromycin aminonucleoside nephrosis rats. Nakamura, K., Kojima, K., Arai, T., Shirai, M., Usutani, S., Akimoto, H., Masaoka, H., Nagase, M., Yamamoto, M. Eur. J. Clin. Invest. (1998)
- Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride. Nakamura, T., Kawagoe, Y., Matsuda, T., Ueda, Y., Ebihara, I., Koide, H. Diabetes Metab. Res. Rev. (2005)
- Effect of dilazep hydrochlorideon the Im munohistopathology of IgA nephropathy in ddY mice. Hayashi, T., Kaneko, S., Thang, N.T., Shou, I., Shirato, I., Tomino, Y. Nephron (2000)
- Phasic blood flow velocity pattern in epimyocardial microvessels in the beating canine left ventricle. Ashikawa, K., Kanatsuka, H., Suzuki, T., Takishima, T. Circ. Res. (1986)
- Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. Visser, F., Vickers, M.F., Ng, A.M., Baldwin, S.A., Young, J.D., Cass, C.E. J. Biol. Chem. (2002)
- Interaction of [3H]dilazep at nucleoside transporter-associated binding sites on S49 mouse lymphoma cells. Gati, W.P., Paterson, A.R. Mol. Pharmacol. (1989)
- 2-chloroadenosine stimulates granule exocytosis from mouse natural killer cells: evidence for signal transduction through a novel extracellular receptor. Williams, B.A., Blay, J., Hoskin, D.W. Exp. Cell Res. (1997)
- Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep. Agarwal, K.C., Zielinski, B.A., Maitra, R.S. Thromb. Haemost. (1989)
- Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Nakamura, T., Ushiyama, C., Shimada, N., Sekizuka, K., Ebihara, I., Hara, M., Koide, H. Diabetes Care (2000)
- Decrease in equilibrative uridine transport during monocytic differentiation of HL-60 leukaemia: involvement of protein kinase C. Lee, C.W. Biochem. J. (1994)
- Effects of verapamil, nifedipine, and dilazep on left ventricular relaxation in the conscious dog. Pagani, M., Pizzinelli, P., Furlan, R., Guzzetti, S., Rimoldi, O., Sandrone, G. Cardiovasc. Res. (1987)
- 2'-deoxyadenosine induces apoptosis in rat chromaffin cells. Wakade, A.R., Guo, X., Palmer, K.C., Kulkarni, J.S., Przywara, D.A., Wakade, T.D. J. Neurochem. (1996)
- Inhibition of nucleoside and nucleobase transport and nitrobenzylthioinosine binding by dilazep and hexobendine. Plagemann, P.G., Kraupp, M. Biochem. Pharmacol. (1986)
- K-7259, a novel dilazep derivative, and d-propranolol attenuate H2O2-induced cell damage. Hoque, N., Hoque, A.N., Hashizume, H., Ichihara, K., Abiko, Y. J. Pharmacol. Exp. Ther. (1996)
- Inhibition of glucose uptake in murine cardiomyocyte cell line HL-1 by cardioprotective drugs dilazep and dipyridamole. Shuralyova, I., Tajmir, P., Bilan, P.J., Sweeney, G., Coe, I.R. Am. J. Physiol. Heart Circ. Physiol. (2004)
- Residue 33 of human equilibrative nucleoside transporter 2 is a functionally important component of both the dipyridamole and nucleoside binding sites. Visser, F., Zhang, J., Raborn, R.T., Baldwin, S.A., Young, J.D., Cass, C.E. Mol. Pharmacol. (2005)
- Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. Endres, C.J., Sengupta, D.J., Unadkat, J.D. Biochem. J. (2004)
- Functional characterization of a recombinant sodium-dependent nucleoside transporter with selectivity for pyrimidine nucleosides (cNT1rat) by transient expression in cultured mammalian cells. Fang, X., Parkinson, F.E., Mowles, D.A., Young, J.D., Cass, C.E. Biochem. J. (1996)
- Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Dawicki, D.D., Agarwal, K.C., Parks, R.E. Biochem. Pharmacol. (1985)
- Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain. Kiss, A., Farah, K., Kim, J., Garriock, R.J., Drysdale, T.A., Hammond, J.R. Biochem. J. (2000)
- Therapeutic tolerance, hemodynamic effects, and oral dose kinetics of dilazep dihydrochloride in hypertensive patients. Sambhi, M.P., Kannan, R., Thananopavarn, C., Ookhtens, M., Gudenzi, M. Journal of pharmaceutical sciences. (1989)
- Effects of dilazep on coronary and systemic hemodynamics in humans. Marzilli, M., Simonetti, I., Levantesi, D., Trivella, M.G., De Nes, M., Perissinotto, A., Puntoni, R., Buzzigoli, G., Boni, C., Michelassi, C. Am. Heart J. (1984)